ClinicalTrials.gg
RecruitingNCT06708741D-ECISIVEUpdated May 4, 2026

Regime for Vitamin D Maintenance in Post-Operative Patients

A Phase 3 interventional study of Vitamin D in Sarcopenia, sponsored by Sengkang General Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Sengkang General Hospital · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

Vitamin D plays a significant part calcium and phosphate haemostasis, thus, intrinsically critical for bone health. Increasing evidence also reveal that insufficient serum vitamin D levels also result in poor muscle health with such individuals having a compromised muscle building potential (4 times slower muscle building).

Muscle health is a critical component of a post-surgical patient recovery, with impaired muscle function leading to reduced functional ability, resulting in a poorer quality of life. Poor muscle health also has negative repercussion on survivability, with reduced overall, and disease-specific survival, especially shown in cancer patients. Thus, maintenance of vitamin D levels post-surgery may be more critical than previously thought.

Read the detailed description

This study is performed in Singapore (outside the US) and the medication, while it is a FDA approved medication, is not manufactured in the US for the trial purpose and the indications of use in this trial is not new.

The investigators would be recruiting patients aged 21-65 years who have undergone major surgery (defined by the NICE criteria) and who are able to provide informed consent, accept to take vitamin D supplements post-operatively and have their serum vitamin D levels checked periodically.

The investigators will excluded patients who have undergone minor procedures (Table code \<4a), those who have a history of chronic kidney disease/end staged renal failure, known hyperparathyroidism, are non-ambulatory independently and have had known allergies to the commercially available high dose vitamin D formulations.

High dose oral vitamin D supplementation (50,000 IU/week for 8 weeks) is the current recommended dose for individuals with vitamin D insufficiency of deficiency and is currently being used for some prehabilitation programmes due to the quick repletion of vitamin D levels to improve muscle gain during the short prehabilitation window prior to surgery.

Using the same dose once a month would provide a significantly less vitamin D supplementation, especially with individuals who have had their vitamin D levels repleted in the preoperative phase. This will be compared against a control who are randomised to standard-of-care (SOC) where high dose vitamin D maintenance is not prescribed.

The unmet clinical need is the still unknown, unstandardised vitamin D supplementation regime. There are current no clinical consensus on vitamin D supplementation after patients who have undergone major surgery.

02

Conditions studied

  • Sarcopenia

Browse trials for

03

In context

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 860 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Sengkang General Hospital is the lead sponsor of 16 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serum 25-hydroxyvitamin D levels between 30-50ng/ml at 4-6 weeks after operation
  • aged 21-65 years
  • ability to provide
  • accepts to take vitamin D supplements post-operatively and
  • have their serum vitamin D levels checked periodically.

Exclusion criteria

Exclusion Criteria:

  • They have undergone minor procedures (Table code \<4a)
  • have a history of chronic kidney disease/end staged renal failure
  • have previous history of ureteric/kidney stones
  • known hyperparathyroidism
  • are non-ambulatory independently
  • have had known allergies to the commercially available high dose vitamin D formulations.
  • Vulnerable personnel would be excluded from the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Vitamin D supplementation

    High dose oral vitamin D supplementation (50,000 IU/once a month)

    Drug: Vitamin D

  • No intervention
    Standard-of-care Arm

    standard of care arm where vitamin D levels are not actively acted upon

Interventions

  • High dose oral vitamin D supplementation (50,000 IU/once per month)

    Also known as: D-cure

06

What researchers measure

Primary outcomes

  1. serum 25-hydroxyvitamin D levels at 3-months post-intervention

    serum 25-hydroxyvitamin D levels at 3-months post-intervention

    Time frame: 3 months after initiation

Secondary outcomes

  1. serum 25-hydroxyvitamin D levels compared to SOC at 6-months post-intervention.

    serum 25-hydroxyvitamin D levels compared to SOC at 6-months post-intervention.

    Time frame: 6 months after initiation

  2. serum 25-hydroxyvitamin D levels compared to SOC at 12-months post-intervention.

    serum 25-hydroxyvitamin D levels compared to SOC at 12-months post-intervention.

    Time frame: 12 months after initiation

  3. functional outcome measures at 3-months post-intervention

    functional outcome measures at 3-months post-intervention

    Time frame: 3-months after intiation

  4. functional outcome measures at 6-months post-intervention

    functional outcome measures at 6-months post-intervention

    Time frame: 6 months after initiation

  5. functional outcome measures at 12-months post-intervention

    functional outcome measures at 12-months post-intervention

    Time frame: 12 months after initiation

  6. muscle quality (Ultrasound+MuscleSound™ evaluation) at 3-months post-intervention

    muscle quality (Ultrasound+MuscleSound™ evaluation) at 3-months post-intervention

    Time frame: 3 months after intiation

  7. muscle quality (Ultrasound+MuscleSound™ evaluation) at 6-months post-intervention

    muscle quality (Ultrasound+MuscleSound™ evaluation) at 6-months post-intervention

    Time frame: 6 months after initiation

  8. muscle quality (Ultrasound+MuscleSound™ evaluation) at 12-months post-intervention

    muscle quality (Ultrasound+MuscleSound™ evaluation) at 12-months post-intervention

    Time frame: 12 months after initiation

  9. quality of life (EQ5D-3L) at 3-months post-intervention

    quality of life (EQ5D-3L) at 3-months post-intervention

    Time frame: 3 months after intiation

  10. quality of life (EQ5D-3L) at 6-months post-intervention

    quality of life (EQ5D-3L) at 6-months post-intervention

    Time frame: 6 months after initiation

  11. quality of life (EQ5D-3L) at 12-months post-intervention

    quality of life (EQ5D-3L) at 12-months post-intervention

    Time frame: 12 months after initiation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Quak GSW, Wang JJD, Yap C, Soh O, Wong O, Tong C, Tay P, Lee HB, Mah SM, Koh FH. Vitamin D maintenance in postoperative patients (D-ECISIVE): a study protocol for a randomized controlled trial. Ann Coloproctol. 2026 Jun;42(3):364-371. doi: 10.3393/ac.2025.01179.0168. Epub 2026 Jun 25. PubMed 42392859 ↗

Individual participant data

Plan to share: No — only centrally available to the PI

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Nov 27, 2024
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06708741
Lead sponsor
Sengkang General Hospital
Collaborators
Hyphens Pharma Pte Ltd
Responsible party
Koh Hong Xiang Frederick (Consultant Colorectal Surgeon, Sengkang General Hospital) — Principal investigator
First posted
Nov 27, 2024
Start date
Jan 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 4, 2026

Study contacts

Frederick H Koh, FRCS, PhD
Contact
frederick.koh.h.x@singhealth.com.sg
6930 6000
Frederick H Koh, FRCS, PhD
principal investigator · Sengkang General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin D

Start the discussion